Member Info for fre1

the same could be said with your post, except you ain't provided any substance - i asked the question and i suspect this is the reality:

£2m +£1.05m loan to Sprift which will probably/maybe convert into equity in Sprift sometime.
£600k worth of shares in BOOM as well.
£3.6m value/ 37.5m shares
Give or take 10p value

maangement have lost a lot of credibility and trust with investors imo following yesterday's news, what a mess. Anyone done the calculations surrounding the net asset worth - must be sub 10p when you add the cash in.

who is the big seller and how much do they have left anyone?

looks that way as blue now

103K buy - II's loading up

Buyers moving in as bargain basement hit

Think many will just look back in a few years time and think these were ridiculously undervalued -tech is there for the future imo

Thanks for this information weathergeek, value zone and expect this to be a mid-cap share going forward, management haven't put a foot wrong here.

down on low volume, high margin profitable business, and in a buoyant business sector - bargains to be had imv

chart points to 10p next stop, this is not what one expected and will be an uphill battle for the company imv.

Yes the key for me was the possibility of long term immunity - just imagine how valuable that would be both in the uk and countries around the world and commercialisation, game changing from here on imo.

other key message from rns is they are planning commercialisation, that's another positive...

"During the trial, EML investigated the possible up-regulation of T-reg cell activity which subject to the data, is thought to promote long term immunity beyond the normal life of a vaccine which is something of much discussion at present and could itself prove to be valuable."

If they can get long term immunity from this process then imagine that will be an added bonus and a huge game changer for this company imv

The last RNS will give TGR a greater footing into the asian market and Hanwa are no small fry either. The global graphene market is estimated to rocket past US $1 billion within next 3 years and TGR in a unique position with its vertically integrated offering. OTCQX listing around the corner and i reckon that will be eaten up by hungry investors too.

Yes, agree high profile endorsement and use by providers is further validation of effectiveness imv. This could well transform the business once FDA approval lands as the COS must be high imo.

rns 7.74% holds 69.5Million now things looking very good with Marr on board

Liberium raises price target to £2.35

looks like we have a buyer- 100k earlier, i expect these will continue their upward trajectory, following the excellent results just announced and they have some big names on their list of customers too.

Results in line with expectations - it says in in the rns, good recovery play in my books

premiums paid by buyer - this one has missed the ride compared with the likes of ZNWD - but are things about to change?